Andrey Morozov

Andrey Morozov

Auto-generated profile, based on publicly available information

Andrey Morozov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Magdalena Rudzinska-RadeckaMagdalena Rudzinska-Radecka
Magdalena Rudzinska-Radecka
Alessandro ParodiAlessandro Parodi
Alessandro Parodi
SSSurinder M Soond
Surinder M Soond
AVAndrey Z. Vinarov
Andrey Z. Vinarov
DKDmitry O. Korolev
Dmitry O. Korolev
Andrey A. Zamyatnin Jr.Andrey A. Zamyatnin Jr.
Andrey A. Zamyatnin Jr.
Cysteine cathepsins are lysosomal enzymes belonging to the papain family. Their expression is misregulated in a wide variety of tumors, and ample data prove their involvement in cancer progression, angiogenesis, metastasis, and in the occurrence of drug resistance. However, while their overexpression is usually associated with highly aggressive tumor phenotypes, their mechanistic role in cancer progression is still to be determined to develop new therapeutic strategies. In this review, we highlight the literature related to the role of the cysteine cathepsins in cancer biology, with particular emphasis on their input into tumor biology.

17 September 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
DEDmitry Enikeev
Dmitry Enikeev
AMAndrey Morozov
Andrey Morozov
MTMark Taratkin
Mark Taratkin
VMVincent Misrai
Vincent Misrai
EREnrique Rijo
Enrique Rijo
THThomas R. W. Herrmann
Thomas R. W. Herrmann

1 February 2020 in Journal of Endourology
Verified
Journal Article
Closed access
AMAndrey Morozov
Andrey Morozov
MTMark Sergeevich Taratkin
Mark Sergeevich Taratkin
VKVasiliy Kozlov
Vasiliy Kozlov
ATAlexander Tarasov
Alexander Tarasov
EBEvgeniy Bezrukov
Evgeniy Bezrukov
DEDmitry Enikeev
Dmitry Enikeev
Introduction: Endoscopic enucleation of the prostate (EEP) is a safe method of treating benign prostatic hyperplasia, regardless of prostate volume and type of applied energy. To date, however, there has been no study that examines complication rates with respect to the type of applied energy. This study aims to address this problem by providing a retrospective analysis of >1400 patients who have undergone prostate enucleation. Materials and Methods: We performed a retrospective analysis of all patients undergoing EEP between 2013 and 2018 at a single tertiary institution. This analysis included patients who had undergone one of three forms of EEP: holmium laser enucleation of the prostate (HoLEP), thulium fiber laser enucleation of the prostate (ThuFLEP), or monopolar enucleation of the prostate (MEP). We compared intraoperative and early postoperative complications, as well as complications at 3 and 6 months follow-up. Results: A total of 1413 patients were included in this study; 36% patients underwent HoLEP, 57.5% had ThuFLEP, and 6.5% MEP. The most frequent complication in the early postoperative period was a mild fever (2.76% of the cases). The morcellation was delayed to a separate stage because of intensive hemorrhaging in 1.4% of the cases. Bladder tamponade was found in 1.1% of the cases. We found no correlation between complication rate and either prostate volume or energy source. Stress urinary incontinence was found in 3.9% of patients at 3 months and in only 1.4% of patients at 6 months after the operation. Urethral stricture at 6 months after the surgery was found in 1.4% of patients, whereas bladder neck sclerosis was found in only 0.9% of these cases. No significant difference was observed between these complication frequencies and any preoperative factors or energy source. Conclusions: All EEP types are safe with equal rates of complications intraoperatively, postoperatively, and at 6 months follow-up.

25 April 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
AMAndrey Morozov
Andrey Morozov
MTMark Taratkin
Mark Taratkin
ABAndrey Bazarkin
Andrey Bazarkin
JRJuan Gómez Rivas
Juan Gómez Rivas
SPStefano Puliatti
Stefano Puliatti
YUYoung Academic Urologists (YAU) Working Group in Uro-technology of the European Association of Urology
Young Academic Urologists (YAU) Working Group in Uro-technology of the European Association of Urology

1 December 2020 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
DEDmitry Enikeev
Dmitry Enikeev
AMAndrey Morozov
Andrey Morozov
MTMark Taratkin
Mark Taratkin
EBEric Barret
Eric Barret
VKVasiliy Kozlov
Vasiliy Kozlov
PGPetr Glybochko
Petr Glybochko

1 October 2020 in Journal of Endourology
Verified
Journal Article
Closed access
DEDmitry Enikeev
Dmitry Enikeev
MTMark Sergeevich Taratkin
Mark Sergeevich Taratkin
AMAndrey Morozov
Andrey Morozov
NSNirmish Singla
Nirmish Singla
SGSvetlana Gabdulina
Svetlana Gabdulina
PGPetr Vitalievich Glybochko
Petr Vitalievich Glybochko
Objective: To analyze the long-term efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia. Materials and Methods: A total of 127 patients who underwent HoLEP at our institution between 2013 and 2015 were included. Patients were observed for 5 years postoperatively. We evaluated the length of the surgery, the mass of the removed tissue, prostate-specific antigen level, the maximal flow rate (Qmax), postvoid residual (PVR), the length of catheterization and hospitalization, and the International Prostate Symptom Score (IPSS) and IPSS quality of life (QoL) at each clinic visit. Results: PVR, Qmax, IPSS, and QoL all improved significantly immediately after the operation ( p < 0.001). By the end of the 5th postoperative year, all the parameters showed a statistically meaningful decline: Qmax reduced by 5.8 mL/s (22.6%) and IPSS by 1.4 points (29.1%). Around 8.6% of the patients continued therapy with α-blockers. There were no differences in efficacy by the age of the patients or the volume of the prostate. Long-term complications and need for repeat operations were not affected by the volume of the prostate or patient age. Conclusions: The improvement of PVR, Qmax, IPSS, and QoL score seen in the early postoperative period after performing HoLEP remains evident at 5 years postoperatively. Long-term complications and the need for reoperation do not depend on the age of the patient or on the initial volume of the prostate.